Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate With Vertebral Fracture as an Index -

Trial Profile

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate With Vertebral Fracture as an Index -

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Mar 2017

At a glance

  • Drugs Ibandronic acid (Primary) ; Risedronic acid
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MOVER
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 15 Sep 2014 Subgroup analysis results presented at the 36th Annual Meeting of the American Society for Bone and Mineral Research.
    • 05 Apr 2014 Results presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 06 Oct 2013 Tolerability results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top